182 related articles for article (PubMed ID: 27899805)
1. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
Mithraprabhu S; Khong T; Ramachandran M; Chow A; Klarica D; Mai L; Walsh S; Broemeling D; Marziali A; Wiggin M; Hocking J; Kalff A; Durie B; Spencer A
Leukemia; 2017 Aug; 31(8):1695-1705. PubMed ID: 27899805
[TBL] [Abstract][Full Text] [Related]
2. DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients.
Mithraprabhu S; Hocking J; Ramachandran M; Choi K; Klarica D; Khong T; Reynolds J; Spencer A
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261969
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.
Mithraprabhu S; Sirdesai S; Chen M; Khong T; Spencer A
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29937522
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
5. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
[TBL] [Abstract][Full Text] [Related]
6. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
7. Detecting circulating tumor DNA in renal cancer: An open challenge.
Corrò C; Hejhal T; Poyet C; Sulser T; Hermanns T; Winder T; Prager G; Wild PJ; Frew I; Moch H; Rechsteiner M
Exp Mol Pathol; 2017 Apr; 102(2):255-261. PubMed ID: 28214514
[TBL] [Abstract][Full Text] [Related]
8. Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.
Mithraprabhu S; Morley R; Khong T; Kalff A; Bergin K; Hocking J; Savvidou I; Bowen KM; Ramachandran M; Choi K; Wong BKL; Reynolds J; Spencer A
Leukemia; 2019 Aug; 33(8):2022-2033. PubMed ID: 30992504
[TBL] [Abstract][Full Text] [Related]
9. Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Ono Y; Sato K; Mizukami Y; Okumura T
Clin Chim Acta; 2023 Nov; 551():117590. PubMed ID: 37837907
[TBL] [Abstract][Full Text] [Related]
10. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
11. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
12. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
14. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
15. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
16. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
17. Monitoring multiple myeloma by quantification of recurrent mutations in serum.
Rustad EH; Coward E; Skytøen ER; Misund K; Holien T; Standal T; Børset M; Beisvag V; Myklebost O; Meza-Zepeda LA; Dai HY; Sundan A; Waage A
Haematologica; 2017 Jul; 102(7):1266-1272. PubMed ID: 28385781
[TBL] [Abstract][Full Text] [Related]
18. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Circulating Tumor DNA.
Mithraprabhu S; Spencer A
Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
